About Rehaler
Rehaler is a Healthcare company based in Aarhus (Denmark) founded in 2009. It operates as an a drug-free inhaler for migraine treatment is provided by Rehaler. Its chief executive is Henrik Olsen. Its focus areas include Life Sciences, Pain Management, Medical Devices and Therapeutic Devices. Its legal entity is REHALER A/S. Its competitors include ElectroCore, ShiraTronics, eNeura, Salvia BioElectronics and Cefaly and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
Rehaler was founded in 2009 in Aarhus, Denmark, and operates in the medical device sector focused on neurology. The companys core offering is the Rehaler device, a non-pharmacological inhaler that employs controlled partial rebreathing to address symptoms during the aura phase of migraines. This approach is utilized by patients seeking alternatives to medication, with development and distribution centered in Europe.
- Headquarters Aarhus, Denmark
- SectorsHealthcare
- Website rehaler.io
- Social LinkedIn
- Legal Name Rehaler A/S
- Net Profit-$714.21 K (USD)-282as on Dec 31, 2022
- Latest Funding Round$1.62M (USD), Grant
Jun 2023
- Investors
Funding Insights of Rehaler
- Total Rounds 1
- Last Round Grant — $1.62M
- First Round $1.62M
(Jun 2023)
- Investors Count 1
All 1 funding rounds of Rehaler with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $1.62M | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Rehaler
Rehaler has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium |
Investor details for Rehaler
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rehaler
1 people are tracked at Rehaler (1 in leadership).
| Name | Role | Group |
|---|---|---|
Henrik Olsen | CEO | Leadership |
Complete people profiles for Rehaler
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Rehaler
2 dated milestones of Rehaler across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Rehaler is founded.
- Funding First funding round of $1.6M.
Competitors of Rehaler
Rehaler has 9 listed competitors in our database, 7 of them funded. They include ElectroCore, ShiraTronics, eNeura, Salvia BioElectronics and Cefaly, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| electrocore.com | 2005 | Basking Ridge, United States | $161.39M | 58 | Non-invasive vagus nerve stimulation devices are developed for headache treatments. | |
| shiratronics.com | 2019 | Minneapolis, United States | $107.69M | – | Neuromodulation devices for migraine and chronic disease treatment are developed. | |
| eneura.com | 2000 | Baltimore, United States | $70.51M | 17 | Transcranial magnetic stimulation devices for migraine treatment are developed. | |
| salviabioelectronics.com | 2017 | Eindhoven, Netherlands | $88.4M | – | Bioelectronic solutions for migraines and neurological disorders are developed. | |
| cefaly.com | 2004 | Seraing, Belgium | – | 12 | Neurostimulation devices for migraine and headache treatment are provided. | |
| zosanopharma.com | 2006 | Fremont, United States | $147.16M | 40 | Develops innovative transdermal drug delivery technologies for various therapeutic applications. | |
| neurolief.com | 2012 | Herzliya, Israel | $5M | – | Wearable neuromodulation devices for neurological disorders are developed. | |
| nocira.com | 2014 | Tempe, United States | $3.9M | – | Device for migraine management | |
| chordate.com | 2005 | Kista, Sweden | – | – | Develops and markets CE-marked devices for migraine and rhinitis treatment. |
Detailed competitors of Rehaler
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pain Management
10 companies that operate in the same segment as Rehaler (Pain Management), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 | |
Therapeutics for migraine treatment are developed using nasal delivery. | 2016 | San Francisco, California, United States | USD 74.13 M | – | 24 | |
Pain treatment products are developed through reformulation technologies. | 2007 | Herzliya, Central District, Israel | USD 12 M | USD 17 K | 6 | |
Drug delivery systems for CNS disorders and pain are developed. | 2006 | Emeryville, California, United States | USD 149.06 M | – | – | |
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment | 2010 | Bloomington, Indiana, United States | USD 530 M | USD 91.65 M | – | |
Therapies for pain and addiction treatment are developed. | 1977 | Saint-cloud, France | USD 248.09 M | USD 167.87 M | – | |
Novel drug products for chronic pain treatment are developed. | 2007 | Blue Bell, Pennsylvania, United States | USD 12.96 M | – | 17 | |
Abuse-deterrent extended-release therapeutics for chronic pain are developed. | 2002 | Canton, Ohio, United States | USD 103 M | USD 780.57 M | 357 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Rehaler
Rehaler was founded in 2009 and raised its 1st funding round 14 years after it was founded.
Rehaler is headquartered in Aarhus, Denmark.
Henrik Olsen is the current CEO of Rehaler.
Rehaler was founded in 2009 in Aarhus, Denmark, and operates in the medical device sector focused on neurology. The companys core offering is the Rehaler device, a non-pharmacological inhaler that employs controlled partial rebreathing to address symptoms during the aura phase of migraines. This approach is utilized by patients seeking alternatives to medication, with development and distribution centered in Europe.
Rehaler's top competitors include Salvia BioElectronics, ShiraTronics and ElectroCore.
Rehaler has 1 investor. Key investors include EIC Fund.
Rehaler operates through Rehaler A/S.